#QuoinPharma #QNRX lands FDA Rare Pediatric Disease Designation for QRX003, targeting the life-threatening skin disorder Netherton Syndrome. The move brings QRX003 closer to a potential NDA and could earn Quoin a valuable Priority Review Voucher.

prismmarketview.com/quoin-pharma...

#QNRX just got the green light from the FDA to launch its second pivotal trial of QRX003 for Netherton Syndrome.
#QuoinPharma #NethertonSyndrome.

prismmarketview.com/quoin-pharma...

Close-up of a person applying a white cream to their forearm, indicating treatment for a skin condition.

#QNRX QRX003 earns EMA Orphan Drug status - A major step forward in developing a much-needed treatment for Netherton Syndrome, a rare and debilitating skin disease.
#QuoinPharma
prismmarketview.com/quoin-pharma...